Castle Biosciences Inc

Castle Biosciences Inc, founded in 2008, is a molecular diagnostics company that focuses on developing innovative tests to guide patient care in various medical conditions. The company offers a portfolio of proprietary tests, including DecisionDx®-Melanoma, DecisionDx®-SCC, DecisionDx®-UM, MyPath® Melanoma, TissueCypher® Barrett’s Esophagus, and IDgenetix®, which provide valuable insights to clinicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions. These tests utilize gene expression profiles to predict the risk of metastasis, recurrence, and other clinical outcomes, helping healthcare providers make informed treatment decisions. Castle Biosciences aims to address unmet clinical needs and improve patient outcomes through its innovative diagnostic solutions.